Cohance Lifesciences Q2 FY26 Concall Decoded: – Revenue flat, ambition still at $1 billion, patience officially on life support

---

1. Opening Hook

If pharma earnings calls were Netflix series, Cohance’s Q2 FY26 would be that season where the plot gets complicated, pacing slows, and the narrator keeps promising a “big payoff next season.” Management walked in armed with slides, science buzzwords, and a billion-dollar dream, while investors walked out clutching spreadsheets and blood pressure pills.

This quarter was supposed to be about integration gains and capability amplification. Instead, it turned into a masterclass on shipment deferrals, biotech winters, plant shutdowns, and revised guidance gymnastics. Somewhere between ADC payloads and oligonucleotides, growth quietly slipped into the next financial year.

Still, the call wasn’t dull. There were approvals, audits, pipeline bragging, and even a rare analyst rant that felt more therapy session than Q&A.

Stick around. It genuinely gets more interesting — and spicier — later.

---

2. At a Glance

• Revenue down 8% YoY: Shipments took a rain check, revenue followed politely.
• Adjusted revenue +14% (ex-restocking): Management’s favourite parallel universe.
• EBITDA margin 23.2%: Investments showed up early; volumes forgot to RSVP.
• H1 revenue +1% YoY: Technically growth. Emotionally debatable.
• Free cash flow ₹1.69 bn: Cash behaved better than profits.
• FY26 guidance cut to flattish: Growth postponed, not cancelled (apparently).

---

3. Management’s Key Commentary

“We are moving from integration to capability amplification.”
(Translation: The hard part isn’t over, we just renamed it.) 😏

“One of our late-phase molecules received U.S. regulatory approval.”
(Translation: Finally, something tangible to point at.)

“We met over 340 customers at CPHI Frankfurt.”
(Translation: Lots of meetings, very few POs.)

“Demand from large innovators remains positive.”
(Translation: They like us, just not enough to ship this quarter.)

“Biotech funding winter has delayed NJ Bio shipments by 2–3 quarters.”
(Translation: Customers ran out of money, not love.)

“Adjusted for restocking, H1 growth was 20%.”
(Translation: Adjust enough and anything grows.) 😬

“We maintain our mid-term $1 billion vision.”
(Translation: The dream survives, timelines negotiable.)

---

4. Numbers Decoded

Source table

Metric	Q2 FY26	YoY Change	Decoded Take
Revenue	₹5,556 mn	-8%	Physics defeated PowerPoint
EBITDA	₹1,289 mn	Down	Fixed costs don’t believe in excuses
EBITDA Margin